Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.

Stefan Willmann, Andrea Kerstin Keller,Michaela Meyer,Dorina van der Mey,Gabriela Wirsching,Yang Zhang,Henk-Jan Drenth,Anne Keunecke, Esmée Vendel,Soundos Saleh

Pediatric pulmonology（2023）

Cited 0|Views8

No score

Abstract

Body size is the main determinant of PK in growing children, and the model supports clinical data that, for children weighing < 50 kg, a bodyweight-adjusted dose of riociguat should be used to achieve a similar exposure to that observed in adults with PAH.

Translated text

Key words

pediatrics,pharmacokinetics,pulmonary hypertension,riociguat

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined